Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 9985 to 9996 of 110998 entries
Sorted by: Best Match Show Resources per page
Continuous Glucose Monitoring and Glycemic Control in Patients With Type 2 Diabetes Mellitus and CKD.

Kidney medicine

Presswala L, Hong S, Harris Y, Romao I, Zhang M, Jhaveri KD, Sakhiya V, Fishbane S.
PMID: 32734208
Kidney Med. 2019 Sep 10;1(5):281-287. doi: 10.1016/j.xkme.2019.07.006. eCollection 2019.

RATIONALE & OBJECTIVE: The accuracy of glycated hemoglobin (HbASTUDY DESIGN: Diagnostic test study of HbASETTING & PARTICIPANTS: Patients with type 2 diabetes and CKD (estimated glomerular filtration rate, 7-45 mL/min, not receiving dialysis) seen in an academic nephrology clinic.TESTS...

Cite
Presswala L, Hong S, Harris Y, et al. Continuous Glucose Monitoring and Glycemic Control in Patients With Type 2 Diabetes Mellitus and CKD. Kidney Med. 2019;1(5):281-287doi: 10.1016/j.xkme.2019.07.006.
Presswala, L., Hong, S., Harris, Y., Romao, I., Zhang, M., Jhaveri, K. D., Sakhiya, V., & Fishbane, S. (2019). Continuous Glucose Monitoring and Glycemic Control in Patients With Type 2 Diabetes Mellitus and CKD. Kidney medicine, 1(5), 281-287. https://doi.org/10.1016/j.xkme.2019.07.006
Presswala, Lubaina, et al. "Continuous Glucose Monitoring and Glycemic Control in Patients With Type 2 Diabetes Mellitus and CKD." Kidney medicine vol. 1,5 (2019): 281-287. doi: https://doi.org/10.1016/j.xkme.2019.07.006
Presswala L, Hong S, Harris Y, Romao I, Zhang M, Jhaveri KD, Sakhiya V, Fishbane S. Continuous Glucose Monitoring and Glycemic Control in Patients With Type 2 Diabetes Mellitus and CKD. Kidney Med. 2019 Sep 10;1(5):281-287. doi: 10.1016/j.xkme.2019.07.006. eCollection 2019. PMID: 32734208; PMCID: PMC7380426.
Copy Download .nbib Format: NLM
Amlodipine-Induced Gingival Overgrowth in a Patient With Uncontrolled Type 2 Diabetes Mellitus With Hypercholesterolemia: A Case Report.

Clinical advances in periodontics

Smitha K.
PMID: 32781818
Clin Adv Periodontics. 2012 May;2(2):115-122. doi: 10.1902/cap.2012.110026.

INTRODUCTION: Gingival overgrowth, with its potential cosmetic implications and for providing new niches for the growth of microorganisms, is a serious concern for both patients and clinicians. Amlodipine is a comparatively new calcium channel blocker and is being used...

Cite
Smitha K. Amlodipine-Induced Gingival Overgrowth in a Patient With Uncontrolled Type 2 Diabetes Mellitus With Hypercholesterolemia: A Case Report. Clin Adv Periodontics. 2012;2(2):115-122doi: 10.1902/cap.2012.110026.
Smitha, K. (2012). Amlodipine-Induced Gingival Overgrowth in a Patient With Uncontrolled Type 2 Diabetes Mellitus With Hypercholesterolemia: A Case Report. Clinical advances in periodontics, 2(2), 115-122. https://doi.org/10.1902/cap.2012.110026
Smitha, K. "Amlodipine-Induced Gingival Overgrowth in a Patient With Uncontrolled Type 2 Diabetes Mellitus With Hypercholesterolemia: A Case Report." Clinical advances in periodontics vol. 2,2 (2012): 115-122. doi: https://doi.org/10.1902/cap.2012.110026
Smitha K. Amlodipine-Induced Gingival Overgrowth in a Patient With Uncontrolled Type 2 Diabetes Mellitus With Hypercholesterolemia: A Case Report. Clin Adv Periodontics. 2012 May;2(2):115-122. doi: 10.1902/cap.2012.110026. PMID: 32781818.
Copy Download .nbib Format: NLM
The Estimating effectiveness from efficacy taxonomy (EFFECT): A tool to estimate the real-world impact of health interventions.

Diabetes research and clinical practice

Galaviz KI, Ali MK, Haw JS, Magee MJ, Kowalski A, Wei J, Straus A, Weber MB, Vos T, Murray C, Narayan KMV.
PMID: 31152807
Diabetes Res Clin Pract. 2020 Jan;159:107751. doi: 10.1016/j.diabres.2019.05.030. Epub 2019 May 29.

AIMS: To develop and pilot test a taxonomy that empirically estimates health intervention effectiveness from efficacy data.METHODS: We developed a taxonomy to score health interventions across 11 items on a scale from 0-100. The taxonomy was pilot-tested in efficacy...

Cite
Galaviz KI, Ali MK, Haw JS, et al. The Estimating effectiveness from efficacy taxonomy (EFFECT): A tool to estimate the real-world impact of health interventions. Diabetes Res Clin Pract. 2019;159:107751doi: 10.1016/j.diabres.2019.05.030.
Galaviz, K. I., Ali, M. K., Haw, J. S., Magee, M. J., Kowalski, A., Wei, J., Straus, A., Weber, M. B., Vos, T., Murray, C., & Narayan, K. M. V. (2020). The Estimating effectiveness from efficacy taxonomy (EFFECT): A tool to estimate the real-world impact of health interventions. Diabetes research and clinical practice, 159107751. https://doi.org/10.1016/j.diabres.2019.05.030
Galaviz, Karla I, et al. "The Estimating effectiveness from efficacy taxonomy (EFFECT): A tool to estimate the real-world impact of health interventions." Diabetes research and clinical practice vol. 159 (2020): 107751. doi: https://doi.org/10.1016/j.diabres.2019.05.030
Galaviz KI, Ali MK, Haw JS, Magee MJ, Kowalski A, Wei J, Straus A, Weber MB, Vos T, Murray C, Narayan KMV. The Estimating effectiveness from efficacy taxonomy (EFFECT): A tool to estimate the real-world impact of health interventions. Diabetes Res Clin Pract. 2020 Jan;159:107751. doi: 10.1016/j.diabres.2019.05.030. Epub 2019 May 29. PMID: 31152807; PMCID: PMC6883153.
Copy Download .nbib Format: NLM
CD40, a Novel Inducer of Purinergic Signaling: Implications to the Pathogenesis of Experimental Diabetic Retinopathy.

Vision (Basel, Switzerland)

Subauste CS.
PMID: 31740645
Vision (Basel). 2017 Aug 12;1(3). doi: 10.3390/vision1030020.

Diabetic retinopathy is a leading complication of diabetes. Death of capillary cells with resulting capillary degeneration is a central feature of this disease. Chronic low-grade inflammation has been linked to the development of retinal capillary degeneration in diabetes. CD40...

Cite
Subauste CS. CD40, a Novel Inducer of Purinergic Signaling: Implications to the Pathogenesis of Experimental Diabetic Retinopathy. Vision (Basel). 2017;1(3)doi: 10.3390/vision1030020.
Subauste, C. S. (2017). CD40, a Novel Inducer of Purinergic Signaling: Implications to the Pathogenesis of Experimental Diabetic Retinopathy. Vision (Basel, Switzerland), 1(3), . https://doi.org/10.3390/vision1030020
Subauste, Carlos S. "CD40, a Novel Inducer of Purinergic Signaling: Implications to the Pathogenesis of Experimental Diabetic Retinopathy." Vision (Basel, Switzerland) vol. 1,3 (2017). doi: https://doi.org/10.3390/vision1030020
Subauste CS. CD40, a Novel Inducer of Purinergic Signaling: Implications to the Pathogenesis of Experimental Diabetic Retinopathy. Vision (Basel). 2017 Aug 12;1(3). doi: 10.3390/vision1030020. PMID: 31740645; PMCID: PMC6835793.
Copy Download .nbib Format: NLM
Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland.

Diabetes, metabolic syndrome and obesity : targets and therapy

Thomann R, Zechmann S, Alexander-David N, Jornayvaz FR.
PMID: 32753920
Diabetes Metab Syndr Obes. 2020 Jul 03;13:2359-2365. doi: 10.2147/DMSO.S252667. eCollection 2020.

INTRODUCTION: Insulin glargine 300 U/mL (Gla-300; ToujeoPATIENTS AND METHODS: We report the 12 months results of the Swiss cohort of Toujeo-1, a prospective, observational multicenter study exploring the real-world effectiveness of Gla-300 in adult patients with type 2 diabetes...

Cite
Thomann R, Zechmann S, Alexander-David N, et al. Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland. Diabetes Metab Syndr Obes. 2020;13:2359-2365doi: 10.2147/DMSO.S252667.
Thomann, R., Zechmann, S., Alexander-David, N., & Jornayvaz, F. R. (2020). Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland. Diabetes, metabolic syndrome and obesity : targets and therapy, 132359-2365. https://doi.org/10.2147/DMSO.S252667
Thomann, Robert, et al. "Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland." Diabetes, metabolic syndrome and obesity : targets and therapy vol. 13 (2020): 2359-2365. doi: https://doi.org/10.2147/DMSO.S252667
Thomann R, Zechmann S, Alexander-David N, Jornayvaz FR. Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland. Diabetes Metab Syndr Obes. 2020 Jul 03;13:2359-2365. doi: 10.2147/DMSO.S252667. eCollection 2020. PMID: 32753920; PMCID: PMC7342388.
Copy Download .nbib Format: NLM
Systolic Blood Pressure, Cardiovascular Mortality, and All-Cause Mortality in Normoglycemia, Prediabetes, and Diabetes.

Diabetes, metabolic syndrome and obesity : targets and therapy

Chen CL, Liu L, Huang JY, Yu YL, Lo K, Huang YQ, Feng YQ.
PMID: 32753922
Diabetes Metab Syndr Obes. 2020 Jul 06;13:2375-2388. doi: 10.2147/DMSO.S260990. eCollection 2020.

BACKGROUND: The optimal blood pressure (BP) level for diabetic patients remains controversial, while studies provided limited evidence on BP management for individuals with normoglycemia or prediabetes. We aimed to investigate the associations between systolic blood pressure (SBP) and all-cause...

Cite
Chen CL, Liu L, Huang JY, et al. Systolic Blood Pressure, Cardiovascular Mortality, and All-Cause Mortality in Normoglycemia, Prediabetes, and Diabetes. Diabetes Metab Syndr Obes. 2020;13:2375-2388doi: 10.2147/DMSO.S260990.
Chen, C. L., Liu, L., Huang, J. Y., Yu, Y. L., Lo, K., Huang, Y. Q., & Feng, Y. Q. (2020). Systolic Blood Pressure, Cardiovascular Mortality, and All-Cause Mortality in Normoglycemia, Prediabetes, and Diabetes. Diabetes, metabolic syndrome and obesity : targets and therapy, 132375-2388. https://doi.org/10.2147/DMSO.S260990
Chen, Chao-Lei, et al. "Systolic Blood Pressure, Cardiovascular Mortality, and All-Cause Mortality in Normoglycemia, Prediabetes, and Diabetes." Diabetes, metabolic syndrome and obesity : targets and therapy vol. 13 (2020): 2375-2388. doi: https://doi.org/10.2147/DMSO.S260990
Chen CL, Liu L, Huang JY, Yu YL, Lo K, Huang YQ, Feng YQ. Systolic Blood Pressure, Cardiovascular Mortality, and All-Cause Mortality in Normoglycemia, Prediabetes, and Diabetes. Diabetes Metab Syndr Obes. 2020 Jul 06;13:2375-2388. doi: 10.2147/DMSO.S260990. eCollection 2020. PMID: 32753922; PMCID: PMC7352464.
Copy Download .nbib Format: NLM
Integrated Datasets of Proteomic and Metabolomic Biomarkers to Predict Its Impacts on Comorbidities of Type 2 Diabetes Mellitus.

Diabetes, metabolic syndrome and obesity : targets and therapy

Cheema AK, Kaur P, Fadel A, Younes N, Zirie M, Rizk NM.
PMID: 32753925
Diabetes Metab Syndr Obes. 2020 Jul 07;13:2409-2431. doi: 10.2147/DMSO.S244432. eCollection 2020.

OBJECTIVE: The objective of the current study is to accomplish a relative exploration of the biological roles of differentially dysregulated genes (DRGs) in type 2 diabetes mellitus (T2DM). The study aimed to determine the impact of these DRGs on...

Cite
Cheema AK, Kaur P, Fadel A, et al. Integrated Datasets of Proteomic and Metabolomic Biomarkers to Predict Its Impacts on Comorbidities of Type 2 Diabetes Mellitus. Diabetes Metab Syndr Obes. 2020;13:2409-2431doi: 10.2147/DMSO.S244432.
Cheema, A. K., Kaur, P., Fadel, A., Younes, N., Zirie, M., & Rizk, N. M. (2020). Integrated Datasets of Proteomic and Metabolomic Biomarkers to Predict Its Impacts on Comorbidities of Type 2 Diabetes Mellitus. Diabetes, metabolic syndrome and obesity : targets and therapy, 132409-2431. https://doi.org/10.2147/DMSO.S244432
Cheema, Amrita K, et al. "Integrated Datasets of Proteomic and Metabolomic Biomarkers to Predict Its Impacts on Comorbidities of Type 2 Diabetes Mellitus." Diabetes, metabolic syndrome and obesity : targets and therapy vol. 13 (2020): 2409-2431. doi: https://doi.org/10.2147/DMSO.S244432
Cheema AK, Kaur P, Fadel A, Younes N, Zirie M, Rizk NM. Integrated Datasets of Proteomic and Metabolomic Biomarkers to Predict Its Impacts on Comorbidities of Type 2 Diabetes Mellitus. Diabetes Metab Syndr Obes. 2020 Jul 07;13:2409-2431. doi: 10.2147/DMSO.S244432. eCollection 2020. PMID: 32753925; PMCID: PMC7354282.
Copy Download .nbib Format: NLM
Aerobic Exercise and Metabolic Syndrome: The Role of Sympathetic Activity and the Redox System.

Diabetes, metabolic syndrome and obesity : targets and therapy

Monda V, Sessa F, Ruberto M, Carotenuto M, Marsala G, Monda M, Cambria MT, Astuto M, Distefano A, Messina G.
PMID: 32753926
Diabetes Metab Syndr Obes. 2020 Jul 08;13:2433-2442. doi: 10.2147/DMSO.S257687. eCollection 2020.

BACKGROUND: Aerobic exercise can greatly assist in reducing collateral effects of metabolic syndrome (MetS). Moreover, aerobic exercise is associated with sympathetic activation and adaptive responses to sustain muscle engagement, changes in the release of Orexin A, a pleiotropic neuropeptide.AIM:...

Cite
Monda V, Sessa F, Ruberto M, et al. Aerobic Exercise and Metabolic Syndrome: The Role of Sympathetic Activity and the Redox System. Diabetes Metab Syndr Obes. 2020;13:2433-2442doi: 10.2147/DMSO.S257687.
Monda, V., Sessa, F., Ruberto, M., Carotenuto, M., Marsala, G., Monda, M., Cambria, M. T., Astuto, M., Distefano, A., & Messina, G. (2020). Aerobic Exercise and Metabolic Syndrome: The Role of Sympathetic Activity and the Redox System. Diabetes, metabolic syndrome and obesity : targets and therapy, 132433-2442. https://doi.org/10.2147/DMSO.S257687
Monda, Vincenzo, et al. "Aerobic Exercise and Metabolic Syndrome: The Role of Sympathetic Activity and the Redox System." Diabetes, metabolic syndrome and obesity : targets and therapy vol. 13 (2020): 2433-2442. doi: https://doi.org/10.2147/DMSO.S257687
Monda V, Sessa F, Ruberto M, Carotenuto M, Marsala G, Monda M, Cambria MT, Astuto M, Distefano A, Messina G. Aerobic Exercise and Metabolic Syndrome: The Role of Sympathetic Activity and the Redox System. Diabetes Metab Syndr Obes. 2020 Jul 08;13:2433-2442. doi: 10.2147/DMSO.S257687. eCollection 2020. PMID: 32753926; PMCID: PMC7354914.
Copy Download .nbib Format: NLM
Diet as Regulator of Gut Microbiota and its Role in Health and Disease.

Archives of medical research

Sánchez-Tapia M, Tovar AR, Torres N.
PMID: 31593850
Arch Med Res. 2019 Jul;50(5):259-268. doi: 10.1016/j.arcmed.2019.09.004. Epub 2019 Oct 05.

In recent years, the gut microbiota has been of great interest due to its role in maintaining health and its association with the development of different diseases such as obesity and diabetes. The objective of the present review is...

Cite
Sánchez-Tapia M, Tovar AR, Torres N. Diet as Regulator of Gut Microbiota and its Role in Health and Disease. Arch Med Res. 2019;50(5):259-268doi: 10.1016/j.arcmed.2019.09.004.
Sánchez-Tapia, M., Tovar, A. R., & Torres, N. (2019). Diet as Regulator of Gut Microbiota and its Role in Health and Disease. Archives of medical research, 50(5), 259-268. https://doi.org/10.1016/j.arcmed.2019.09.004
Sánchez-Tapia, Mónica, et al. "Diet as Regulator of Gut Microbiota and its Role in Health and Disease." Archives of medical research vol. 50,5 (2019): 259-268. doi: https://doi.org/10.1016/j.arcmed.2019.09.004
Sánchez-Tapia M, Tovar AR, Torres N. Diet as Regulator of Gut Microbiota and its Role in Health and Disease. Arch Med Res. 2019 Jul;50(5):259-268. doi: 10.1016/j.arcmed.2019.09.004. Epub 2019 Oct 05. PMID: 31593850.
Copy Download .nbib Format: NLM
Evaluation of the suitability of 19 pharmacogenomics biomarkers for individualized metformin therapy for type 2 diabetes patients.

Drug metabolism and personalized therapy

Xhakaza L, Abrahams-October Z, Pearce B, Masilela CM, Adeniyi OV, Johnson R, Ongole JJ, Benjeddou M.
PMID: 32609649
Drug Metab Pers Ther. 2020 Jun 30; doi: 10.1515/dmdi-2020-0111. Epub 2020 Jun 30.

Objectives Type 2 Diabetes mellitus is a progressive metabolic disease characterized by relative insulin insufficiency and insulin resistance resulting in hyperglycemia. Despite the widespread use of metformin, there is considerable variation in treatment response; with approximately one-third of patients...

Cite
Xhakaza L, Abrahams-October Z, Pearce B, et al. Evaluation of the suitability of 19 pharmacogenomics biomarkers for individualized metformin therapy for type 2 diabetes patients. Drug Metab Pers Ther. 2020;doi: 10.1515/dmdi-2020-0111.
Xhakaza, L., Abrahams-October, Z., Pearce, B., Masilela, C. M., Adeniyi, O. V., Johnson, R., Ongole, J. J., & Benjeddou, M. (2020). Evaluation of the suitability of 19 pharmacogenomics biomarkers for individualized metformin therapy for type 2 diabetes patients. Drug metabolism and personalized therapy, . https://doi.org/10.1515/dmdi-2020-0111
Xhakaza, Lettilia, et al. "Evaluation of the suitability of 19 pharmacogenomics biomarkers for individualized metformin therapy for type 2 diabetes patients." Drug metabolism and personalized therapy vol. (2020). doi: https://doi.org/10.1515/dmdi-2020-0111
Xhakaza L, Abrahams-October Z, Pearce B, Masilela CM, Adeniyi OV, Johnson R, Ongole JJ, Benjeddou M. Evaluation of the suitability of 19 pharmacogenomics biomarkers for individualized metformin therapy for type 2 diabetes patients. Drug Metab Pers Ther. 2020 Jun 30; doi: 10.1515/dmdi-2020-0111. Epub 2020 Jun 30. PMID: 32609649.
Copy Download .nbib Format: NLM
Specific impact of past and new major cardiovascular events on acute kidney injury and end-stage renal disease risks in diabetes: a dynamic view.

Clinical kidney journal

Pinier C, Gatault P, Fauchier L, Angoulvant D, François M, Barbet C, Bailly E, Noble J, Chevallier E, Rabot N, Büchler M, Sautenet B, Halimi JM.
PMID: 32083616
Clin Kidney J. 2019 Apr 16;13(1):17-23. doi: 10.1093/ckj/sfz028. eCollection 2020 Feb.

BACKGROUND: Interconnections between major cardiovascular events (MCVEs) and renal events are recognized in diabetes, however, the specific impact of atrial fibrillation (AF), heart failure (HF) and acute coronary syndrome (ACS) on the risk of end-stage renal disease (ESRD) on...

Cite
Pinier C, Gatault P, Fauchier L, et al. Specific impact of past and new major cardiovascular events on acute kidney injury and end-stage renal disease risks in diabetes: a dynamic view. Clin Kidney J. 2019;13(1):17-23doi: 10.1093/ckj/sfz028.
Pinier, C., Gatault, P., Fauchier, L., Angoulvant, D., François, M., Barbet, C., Bailly, E., Noble, J., Chevallier, E., Rabot, N., Büchler, M., Sautenet, B., & Halimi, J. M. (2020). Specific impact of past and new major cardiovascular events on acute kidney injury and end-stage renal disease risks in diabetes: a dynamic view. Clinical kidney journal, 13(1), 17-23. https://doi.org/10.1093/ckj/sfz028
Pinier, Cédric, et al. "Specific impact of past and new major cardiovascular events on acute kidney injury and end-stage renal disease risks in diabetes: a dynamic view." Clinical kidney journal vol. 13,1 (2020): 17-23. doi: https://doi.org/10.1093/ckj/sfz028
Pinier C, Gatault P, Fauchier L, Angoulvant D, François M, Barbet C, Bailly E, Noble J, Chevallier E, Rabot N, Büchler M, Sautenet B, Halimi JM. Specific impact of past and new major cardiovascular events on acute kidney injury and end-stage renal disease risks in diabetes: a dynamic view. Clin Kidney J. 2019 Apr 16;13(1):17-23. doi: 10.1093/ckj/sfz028. eCollection 2020 Feb. PMID: 32083616; PMCID: PMC7025370.
Copy Download .nbib Format: NLM
Impact of different stages of chronic kidney disease on the severity of Willis-Ekbom disease.

Journal of family medicine and primary care

Bhagawati J, Kumar S, Agrawal AK, Acharya S, Wanjari AK, Kamble TK.
PMID: 30984650
J Family Med Prim Care. 2019 Feb;8(2):432-436. doi: 10.4103/jfmpc.jfmpc_418_18.

INTRODUCTION: Willis-Ekbom disease (WED)/restless legs syndrome (RLS) is a disorder in which the patient has neurologic features such as urge of rhythmic limb movement that may decrease or stop when the limb is moved. In this study, we had...

Cite
Bhagawati J, Kumar S, Agrawal AK, et al. Impact of different stages of chronic kidney disease on the severity of Willis-Ekbom disease. J Family Med Prim Care. 2019;8(2):432-436doi: 10.4103/jfmpc.jfmpc_418_18.
Bhagawati, J., Kumar, S., Agrawal, A. K., Acharya, S., Wanjari, A. K., & Kamble, T. K. (2019). Impact of different stages of chronic kidney disease on the severity of Willis-Ekbom disease. Journal of family medicine and primary care, 8(2), 432-436. https://doi.org/10.4103/jfmpc.jfmpc_418_18
Bhagawati, Jahnabi, et al. "Impact of different stages of chronic kidney disease on the severity of Willis-Ekbom disease." Journal of family medicine and primary care vol. 8,2 (2019): 432-436. doi: https://doi.org/10.4103/jfmpc.jfmpc_418_18
Bhagawati J, Kumar S, Agrawal AK, Acharya S, Wanjari AK, Kamble TK. Impact of different stages of chronic kidney disease on the severity of Willis-Ekbom disease. J Family Med Prim Care. 2019 Feb;8(2):432-436. doi: 10.4103/jfmpc.jfmpc_418_18. PMID: 30984650; PMCID: PMC6436266.
Copy Download .nbib Format: NLM
Showing 9985 to 9996 of 110998 entries